Joanna Daffy - Ortivus AB Marketing Mang
| ORTI-B Stock | SEK 1.22 0.02 1.67% |
Insider
Joanna Daffy is Marketing Mang of Ortivus AB ser
| Phone | 46 84 46 45 00 |
| Web | https://www.ortivus.com |
Ortivus AB Management Efficiency
The company has return on total asset (ROA) of 0.0822 % which means that it generated a profit of $0.0822 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.2336 %, meaning that it generated $0.2336 on every $100 dollars invested by stockholders. Ortivus AB's management efficiency ratios could be used to measure how well Ortivus AB manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | INSIDER Age | ||
| Claes Lindblad | Modus Therapeutics Holding | 56 | |
| Jakob Lind | Qlife Holding AB | N/A | |
| Nicklas Rosendal | Prostatype Genomics AB | N/A | |
| Keith Alexander | ExpreS2ion Biotech Holding | N/A | |
| John MD | Modus Therapeutics Holding | 52 | |
| Michael Winklerfelt | Prostatype Genomics AB | 51 | |
| Fernando Andreu | 2cureX AB | 59 | |
| Fredrik Hellqvist | Newbury Pharmaceuticals AB | 50 | |
| Henrik Ljung | SpectraCure AB | 65 | |
| Mirjam Johansson | SpectraCure AB | N/A | |
| Johannes Swartling | SpectraCure AB | 51 | |
| Bent MSc | ExpreS2ion Biotech Holding | N/A | |
| Pr Laurell | AcouSort AB | 62 | |
| Torsten Freltoft | AcouSort AB | 65 | |
| Ole VD | 2cureX AB | 70 | |
| Hans Lilja | AcouSort AB | N/A | |
| Gunnar Telhammar | AcouSort AB | 62 | |
| Lars Minor | Newbury Pharmaceuticals AB | 53 | |
| Thomas Warthoe | Qlife Holding AB | 56 | |
| Karl Karlsson | Newbury Pharmaceuticals AB | 49 | |
| Kenneth Johansen | 2cureX AB | 47 | |
Management Performance
| Return On Equity | 0.23 | |||
| Return On Asset | 0.0822 |
Ortivus AB ser Leadership Team
Elected by the shareholders, the Ortivus AB's board of directors comprises two types of representatives: Ortivus AB inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Ortivus. The board's role is to monitor Ortivus AB's management team and ensure that shareholders' interests are well served. Ortivus AB's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Ortivus AB's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Joanna Daffy, Marketing Mang | ||
| Magnus Mrtensson, Chief Officer | ||
| Thomas Pasold, Managing AG | ||
| Reidar Gardeback, Chief Officer | ||
| Philip Swan, Managing Ltd | ||
| Viveka Ornas, Chief Officer | ||
| Jonas Bergh, S Board | ||
| Elias Obaid, Customer Mang |
Ortivus Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Ortivus AB a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.23 | |||
| Return On Asset | 0.0822 | |||
| Profit Margin | 0.08 % | |||
| Operating Margin | 0.1 % | |||
| Current Valuation | 232.78 M | |||
| Shares Outstanding | 42.6 M | |||
| Shares Owned By Insiders | 38.33 % | |||
| Shares Owned By Institutions | 30.45 % | |||
| Price To Earning | (17.16) X | |||
| Price To Book | 6.65 X |
Thematic Opportunities
Explore Investment Opportunities
Other Information on Investing in Ortivus Stock
Ortivus AB financial ratios help investors to determine whether Ortivus Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Ortivus with respect to the benefits of owning Ortivus AB security.